Cargando…

Impact of Adalimumab Patient Support Program’s Care Coach Calls on Clinical Outcomes in Patients with Crohn’s Disease in Canada: An Observational Retrospective Cohort Study

BACKGROUND: Adalimumab is an antitumour necrosis factor (TNFα) biologic therapy indicated for the treatment of Crohn’s disease (CD). Patients receiving adalimumab in Canada are eligible to enroll in the AbbVie Care™ patient support program (AC-PSP), which provides personalized services, including ca...

Descripción completa

Detalles Bibliográficos
Autores principales:	Narula, Neeraj, Millson, Brad, Charland, Katia, Donepudi, Krishna, Gaetano, Tania, McHugh, Kevin, Latour, Martin G, Gazel, Sandra, Laliberté, Marie-Claude, Marshall, John K
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2018
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6542296/ https://www.ncbi.nlm.nih.gov/pubmed/31294360 http://dx.doi.org/10.1093/jcag/gwy059

Ejemplares similares

Adalimumab in Crohn’s disease
por: Van Assche, Gert, et al.
Publicado: (2007)

Adalimumab for the treatment of Crohn’s disease
por: Cassinotti, Andrea, et al.
Publicado: (2008)

Adalimumab for the treatment of fistulas in patients with Crohn’s disease
por: Colombel, J-F, et al.
Publicado: (2009)

Management of Crohn’s disease in poor responders to adalimumab
por: de Boer, Nanne KH, et al.
Publicado: (2014)

Efficacy of Adalimumab in Korean Patients with Crohn’s Disease
por: Sohn, Il Woong, et al.
Publicado: (2016)

A Meta-Analysis of Adalimumab for Fistula in Crohn's Disease
por: Fu, Yin-mei, et al.
Publicado: (2017)

Difficult-to-treat-pediatric Crohn’s disease: focus on adalimumab
por: Zeisler, Bella, et al.
Publicado: (2015)

Adalimumab Therapy Improves Intestinal Dysbiosis in Crohn’s Disease
por: Ribaldone, Davide Giuseppe, et al.
Publicado: (2019)

Leukocytoclastic Vasculitis Associated with Adalimumab Therapy for Crohn’s Disease
por: Xu, Lankai Cathy, et al.
Publicado: (2023)

Cost-Effectiveness of Tight Control for Crohn’s Disease With Adalimumab-Based Treatment: Economic Evaluation of the CALM Trial From a Canadian Perspective
por: Lakatos, Peter L, et al.
Publicado: (2022)

Adalimumab Effectiveness Up to Six Years in Adalimumab-naïve Patients with Crohn’s Disease: Results of the PYRAMID Registry
por: Loftus, Edward V, et al.
Publicado: (2019)

Mesenteric Fibromatosis in Crohn's Disease as a Potential Effect of Adalimumab
por: Abdelqader, Abdelhai, et al.
Publicado: (2016)

Listeria Monocytogenes Brain Abscess in Crohn's Disease Treated with Adalimumab
por: Atsawarungruangkit, Amporn, et al.
Publicado: (2017)

Adalimumab or infliximab: which is better for perianal fistula in Crohn's disease?
por: Im, Jong Pil
Publicado: (2017)

Call the Coach: Opportunities and Challenges for Parent Coaching in Pediatric Type 1 Diabetes
por: Streisand, Randi
Publicado: (2021)

Infliximab-graded challenge in a patient with Crohn’s disease and adalimumab hypersensitivity
por: Song, Christine H, et al.
Publicado: (2012)

Reversible proteinuria after adalimumab discontinuation in a patient with Crohn's disease
por: Katsanos, Konstantinos H., et al.
Publicado: (2010)

Isolated Bilateral Gastrocnemius Myositis in Crohn Disease Successfully Treated with Adalimumab
por: Vadala di Prampero, Salvatore, et al.
Publicado: (2016)

Anti–NMDAR encephalitis in a patient with Crohn disease receiving adalimumab
por: Noble, Geoffrey P., et al.
Publicado: (2018)

Long-term Efficacy and Safety of Adalimumab in Pediatric Patients with Crohn's Disease
por: Faubion, William A., et al.
Publicado: (2017)

Distinct alterations of fecal microbiota refer to the efficacy of adalimumab in Crohn’s disease
por: Chen, Liang, et al.
Publicado: (2022)

Adherence to and Persistence with Adalimumab Therapy among Swedish Patients with Crohn’s Disease
por: Liu, Yifei, et al.
Publicado: (2022)

CNS TB-IRIS Following Cessation of Adalimumab in an Adolescent With Crohn’s Disease
por: Christian, Elizabeth, et al.
Publicado: (2022)

Vitiligo during Treatment of Crohn's Disease with Adalimumab: Adverse Effect or Co-Occurrence?
por: Posada, Celia, et al.
Publicado: (2011)

Safety of Adalimumab and Predictors of Adverse Events in 1693 Japanese Patients with Crohn’s Disease
por: Ogata, Haruhiko, et al.
Publicado: (2016)

Subtherapeutic concentrations of infliximab and adalimumab are associated with increased disease activity in Crohn’s disease
por: Carlsen, Arne, et al.
Publicado: (2018)

Primary Cutaneous Nocardiosis in a Patient Taking Adalimumab Therapy for Crohn’s Disease
por: Desai, Madhav, et al.
Publicado: (2017)

Administration Timing Is the Best Clinical Outcome Predictor for Adalimumab Administration in Crohn's Disease
por: Mastronardi, Mauro, et al.
Publicado: (2019)

Clinical Practice of Adalimumab and Infliximab Biosimilar Treatment in Adult Patients With Crohn’s Disease
por: Reinisch, Walter, et al.
Publicado: (2020)

Nodular Pachymeningitis Associated With Relapsing Polychondritis and Crohn Disease Responsive to Adalimumab and Prednisone
por: Hutto, Spencer K., et al.
Publicado: (2021)

Langerhans Cell Histiocytosis Caused by Adalimumab for Crohn’s Disease: A Case Report
por: KOCHI, Mariko, et al.
Publicado: (2023)

Long-Term Clinical Remission in Biologically Naïve Crohn's Disease Patients with Adalimumab Therapy, Including Analyses of Switch from Adalimumab to Infliximab
por: Mizoshita, Tsutomu, et al.
Publicado: (2016)

Adalimumab Dose-Escalation Therapy Is Effective in Refractory Crohn's Disease Patients with Loss of Response to Adalimumab, Especially in Cases without Previous Infliximab Treatment
por: Suzuki, Taketo, et al.
Publicado: (2019)

The impact of ustekinumab on extraintestinal manifestations of Crohn's disease: A post hoc analysis of the UNITI studies
por: Narula, Neeraj, et al.
Publicado: (2021)

Adalimumab - an effective and promising treatment for patients with fistulizing Crohn's disease: a case series
por: Kouklakis, George, et al.
Publicado: (2011)

Efficacy and Safety of Escalation of Adalimumab Therapy to Weekly Dosing in Pediatric Patients with Crohn's Disease
por: Dubinsky, Marla C., et al.
Publicado: (2016)

Clinical efficacy of adalimumab in Crohn’s disease: a real practice observational study in Japan
por: Takeshima, Fuminao, et al.
Publicado: (2016)

Fulminant Herpes Simplex Hepatitis Secondary to Adalimumab in Crohn’s Disease: A Case Report
por: Goel, Kanika, et al.
Publicado: (2019)

Adalimumab for endoscopic and histopathological mucosal healing in paediatric patients with moderate to severe Crohn’s disease
por: Szymanska, Edyta, et al.
Publicado: (2016)

Determination of lower cut‐off levels of adalimumab associated with biochemical remission in Crohn's disease
por: Carlsen, Arne, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_iifoj3347p2dm08p2q85ihbadn